This is expected to occur increasingly, now that BRCA1/2 mutation-prediction programs such as BOADICEA include pathology as a component [16], and given recent evidence supporting implementation of the National Comprehensive Cancer Network (NCCN) guidelines that recommend testing of all TN breast cancer patients aged 60 years or younger [45]. Here, BRCA1 is linked to breast carcinoma.